Evolving therapeutic concepts in prostate cancer based on genome-wide analyses (Review)

Georgi,Björn; Korzeniewski,Nina; Hadaschik,Boris; Grüllich,Carsten; Roth,Wilfried; Sültmann,Holger; Pahernik,Sascha; Hohenfellner,Markus; Duensing,Stefan

doi:10.3892/ijo.2014.2567

Evolving therapeutic concepts in prostate cancer based on genome-wide analyses (Review)

Authors:
- Björn Georgi
- Nina Korzeniewski
- Boris Hadaschik
- Carsten Grüllich
- Wilfried Roth
- Holger Sültmann
- Sascha Pahernik
- Markus Hohenfellner
- Stefan Duensing
View Affiliations

Affiliations: Department of Urology, University of Heidelberg School of Medicine, D-69120 Heidelberg, Germany, Section of Molecular Urooncology, Department of Urology, University of Heidelberg School of Medicine, D-69120 Heidelberg, Germany , National Center for Tumor Diseases, Department of Medical Oncology, University of Heidelberg School of Medicine, D-69120 Heidelberg, Germany, Department of Pathology, University of Heidelberg School of Medicine, D-69120 Heidelberg, Germany, Division for Cancer Genome Research, National Center for Tumor Diseases and German Cancer Research Center, D-69120 Heidelberg, Germany
Published online on: July 28, 2014 https://doi.org/10.3892/ijo.2014.2567
Pages: 1337-1344

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Treatment of castration resistant prostate cancer (CRPC) continues to represent a major urooncological challenge due to tumor heterogeneity and the inevitable development of therapy resistance. Although androgen deprivation therapy retains an important role in the management of CRPC, recent evidence suggests that a broader spectrum of therapeutic targets may improve patient response and delay development of advanced disease. Genome-wide analyses have identified four major signaling nodes that are most frequently altered in prostate cancer: i) the androgen receptor (AR); ii) the PI3K pathway; iii) the Ras/Raf/MEK/ERK pathway; and iv) the retinoblastoma protein (pRB) signaling pathway. Extensive crosstalk and redundancy exists between these signaling pathways, which underscores the need for combination therapies. There are several novel AR pathway inhibitors currently in clinical use. Clinical trials are being performed on single-agent PI3K inhibitors with some success in tumors with genetically altered PI3K components. MEK/ERK inhibitors are also in clinical trials and the importance of pRB inactivation in prostate cancer is becoming more widely recognized. A greater understanding of the effects of single agent therapy on compensatory signaling pathway activation that can potentially thwart antitumoral responses is urgently needed and will provide additional insight into the mechanism of therapy resistance and how to further delay the progression to lethal disease.

View Figures

View References

1	Siegel R, Naishadham D and Jemal A: Cancer statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar
2	Prostate Cancer Trialists’ Collaborative Group. Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. Lancet. 355:1491–1498. 2000. View Article : Google Scholar : PubMed/NCBI
3	Berthold DR, Pond GR, Soban F, de Wit R, Eisenberger M and Tannock IF: Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol. 26:242–245. 2008. View Article : Google Scholar : PubMed/NCBI
4	Tannock IF, de Wit R, Berry WR, et al: Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 351:1502–1512. 2004. View Article : Google Scholar : PubMed/NCBI
5	Ryan CJ, Smith MR, de Bono JS, et al: Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med. 368:138–148. 2013. View Article : Google Scholar
6	Beer TM, Armstrong AJ, Sternberg CN, et al: Enzalutamide in men with chemotherapy-naive metastatic prostate cancer (mCRPC): Results of phase III PREVAIL study. J Clin Oncol. 32(Suppl 4): abs. LBA1ˆ. 2014.PubMed/NCBI
7	Taylor BS, Schultz N, Hieronymus H, et al: Integrative genomic profiling of human prostate cancer. Cancer Cell. 18:11–22. 2010. View Article : Google Scholar : PubMed/NCBI
8	Mulholland DJ, Kobayashi N, Ruscetti M, et al: Pten loss and RAS/MAPK activation cooperate to promote EMT and metastasis initiated from prostate cancer stem/progenitor cells. Cancer Res. 72:1878–1889. 2012. View Article : Google Scholar : PubMed/NCBI
9	Carver BS, Chapinski C, Wongvipat J, et al: Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer. Cancer Cell. 19:575–586. 2011. View Article : Google Scholar : PubMed/NCBI
10	Bennett NC, Gardiner RA, Hooper JD, Johnson DW and Gobe GC: Molecular cell biology of androgen receptor signalling. Int J Biochem Cell Biol. 42:813–827. 2010. View Article : Google Scholar : PubMed/NCBI
11	Ryan CJ and Tindall DJ: Androgen receptor rediscovered: the new biology and targeting the androgen receptor therapeutically. J Clin Oncol. 29:3651–3658. 2011. View Article : Google Scholar : PubMed/NCBI
12	Koivisto P, Kononen J, Palmberg C, et al: Androgen receptor gene amplification: a possible molecular mechanism for androgen deprivation therapy failure in prostate cancer. Cancer Res. 57:314–319. 1997.PubMed/NCBI
13	Edwards J, Krishna NS, Grigor KM and Bartlett JM: Androgen receptor gene amplification and protein expression in hormone refractory prostate cancer. Br J Cancer. 89:552–556. 2003. View Article : Google Scholar : PubMed/NCBI
14	Dehm SM, Schmidt LJ, Heemers HV, Vessella RL and Tindall DJ: Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance. Cancer Res. 68:5469–5477. 2008. View Article : Google Scholar : PubMed/NCBI
15	Sun S, Sprenger CC, Vessella RL, et al: Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant. J Clin Invest. 120:2715–2730. 2010. View Article : Google Scholar : PubMed/NCBI
16	Chen S, Xu Y, Yuan X, Bubley GJ and Balk SP: Androgen receptor phosphorylation and stabilization in prostate cancer by cyclin-dependent kinase 1. Proc Natl Acad Sci USA. 103:15969–15974. 2006. View Article : Google Scholar : PubMed/NCBI
17	Fujimoto N, Mizokami A, Harada S and Matsumoto T: Different expression of androgen receptor coactivators in human prostate. Urology. 58:289–294. 2001. View Article : Google Scholar : PubMed/NCBI
18	Taplin ME, Rajeshkumar B, Halabi S, et al: Androgen receptor mutations in androgen-independent prostate cancer: Cancer and Leukemia Group B Study 9663. J Clin Oncol. 21:2673–2678. 2003. View Article : Google Scholar : PubMed/NCBI
19	Sack JS, Kish KF, Wang C, et al: Crystallographic structures of the ligand-binding domains of the androgen receptor and its T877A mutant complexed with the natural agonist dihydrotes-tosterone. Proc Natl Acad Sci USA. 98:4904–4909. 2001. View Article : Google Scholar
20	Stein MN, Patel N, Bershadskiy A, Sokoloff A and Singer EA: Androgen synthesis inhibitors in the treatment of castration-resistant prostate cancer. Asian J Androl. 16:387–400. 2014. View Article : Google Scholar : PubMed/NCBI
21	Abreu-Martin MT, Chari A, Palladino AA, Craft NA and Sawyers CL: Mitogen-activated protein kinase kinase kinase 1 activates androgen receptor-dependent transcription and apoptosis in prostate cancer. Mol Cell Biol. 19:5143–5154. 1999.
22	Bakin RE, Gioeli D, Sikes RA, Bissonette EA and Weber MJ: Constitutive activation of the Ras/mitogen-activated protein kinase signaling pathway promotes androgen hypersensitivity in LNCaP prostate cancer cells. Cancer Res. 63:1981–1989. 2003.
23	Araujo JC, Trudel GC, Saad F, et al: Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer (READY): a randomised, double-blind phase 3 trial. Lancet Oncol. 14:1307–1316. 2013. View Article : Google Scholar : PubMed/NCBI
24	Cea R: Interim analysis results of COU-AA-302, a randomized, phase 3 study of abiraterone acetate (AA) in chemotherapie-naive patients with metastatic castration-resistant prostate cancer (mCRPC). J Clin Oncol. (Suppl 30): abs LBA4518. 2012.
25	De Bono JS, Logothetis CJ, Molina A, et al: Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 364:1995–2005. 2011.
26	Sridhar SS, Freedland SJ, Gleave ME, et al: Castration-resistant prostate cancer: from new pathophysiology to new treatment. Eur Urol. 65:289–299. 2014. View Article : Google Scholar : PubMed/NCBI
27	Tran C, Ouk S, Clegg NJ, et al: Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science. 324:787–790. 2009. View Article : Google Scholar
28	De Bono JS: Primary, secondary, and quality-of-life endpoint results from the phase III AFFIRM study of MDV3100, an androgen receptor signaling inhibitor. J Clin Oncol. (Suppl 30): abs 4519. 2012.
29	Scher HI, Fizazi K, Saad F, et al: Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 367:1187–1197. 2012. View Article : Google Scholar : PubMed/NCBI
30	Clegg NJ, Wongvipat J, Joseph JD, et al: ARN-509: a novel antiandrogen for prostate cancer treatment. Cancer Res. 72:1494–1503. 2012. View Article : Google Scholar : PubMed/NCBI
31	Rathkopf DE, Morris MJ, Fox JJ, et al: Phase I study of ARN-509, a novel antiandrogen, in the treatment of castration-resistant prostate cancer. J Clin Oncol. 31:3525–3530
32	Wong KK, Engelman JA and Cantley LC: Targeting the PI3K signaling pathway in cancer. Curr Opin Genet Dev. 20:87–90. 2010. View Article : Google Scholar : PubMed/NCBI
33	LoPiccolo J, Blumenthal GM, Bernstein WB and Dennis PA: Targeting the PI3K/Akt/mTOR pathway: effective combinations and clinical considerations. Drug Resist Updat. 11:32–50. 2008. View Article : Google Scholar : PubMed/NCBI
34	Vlietstra RJ, van Alewijk DC, Hermans KG, van Steenbrugge GJ and Trapman J: Frequent inactivation of PTEN in prostate cancer cell lines and xenografts. Cancer Res. 58:2720–2723. 1998.PubMed/NCBI
35	Verhagen PC, van Duijn PW, Hermans KG, et al: The PTEN gene in locally progressive prostate cancer is preferentially inactivated by bi-allelic gene deletion. J Pathol. 208:699–707. 2006. View Article : Google Scholar : PubMed/NCBI
36	Konishi N, Nakamura M, Kishi M, Nishimine M, Ishida E and Shimada K: Heterogeneous methylation and deletion patterns of the INK4a/ARF locus within prostate carcinomas. Am J Pathol. 160:1207–1214. 2002. View Article : Google Scholar : PubMed/NCBI
37	Bitting RL and Armstrong AJ: Targeting the PI3K/Akt/mTOR pathway in castration-resistant prostate cancer. Endocr Relat Cancer. 20:R83–R99. 2013. View Article : Google Scholar : PubMed/NCBI
38	Ando Y, Inada-Inoue M, Mitsuma A, et al: Phase I dose-escalation study of buparlisib (BKM120), an oral pan-class I PI3K inhibitor, in Japanese patients with advanced solid tumors. Cancer Sci. 105:347–353
39	Bendell JC, Rodon J, Burris HA, et al: Phase I, dose-escalation study of BKM120, an oral pan-class I PI3K inhibitor, in patients with advanced solid tumors. J Clin Oncol. 30:282–290. 2012. View Article : Google Scholar : PubMed/NCBI
40	Busaidy NL, Farooki A, Dowlati A, et al: Management of metabolic effects associated with anticancer agents targeting the PI3K-Akt-mTOR pathway. J Clin Oncol. 30:2919–2928. 2012. View Article : Google Scholar : PubMed/NCBI
41	Armstrong GT, Kawashima T, Leisenring W, et al: Aging and risk of severe, disabling, life-threatening, and fatal events in the childhood cancer survivor study. J Clin Oncol. 32:1218–1227. 2014. View Article : Google Scholar : PubMed/NCBI
42	McCubrey JA, Steelman LS, Chappell WH, et al: Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta. 1773:1263–1284. 2007. View Article : Google Scholar : PubMed/NCBI
43	McCubrey JA, Steelman LS, Abrams SL, et al: Roles of the Raf/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance. Adv Enzyme Regul. 46:249–279. 2006. View Article : Google Scholar : PubMed/NCBI
44	Ramsay AK, McCracken SR, Soofi M, et al: ERK5 signalling in prostate cancer promotes an invasive phenotype. Br J Cancer. 104:664–672. 2011. View Article : Google Scholar : PubMed/NCBI
45	Kim EK and Choi EJ: Pathological roles of MAPK signaling pathways in human diseases. Biochim Biophys Acta. 1802:396–405. 2010. View Article : Google Scholar : PubMed/NCBI
46	Kinkade CW, Castillo-Martin M, Puzio-Kuter A, et al: Targeting AKT/mTOR and ERK MAPK signaling inhibits hormone-refractory prostate cancer in a preclinical mouse model. J Clin Invest. 118:3051–3064. 2008.PubMed/NCBI
47	Shimizu T, Tolcher AW, Papadopoulos KP, et al: The clinical effect of the dual-targeting strategy involving PI3K/AKT/mTOR and RAS/MEK/ERK pathways in patients with advanced cancer. Clin Cancer Res. 18:2316–2325. 2012. View Article : Google Scholar : PubMed/NCBI
48	Drake JM, Graham NA, Stoyanova T, et al: Oncogene-specific activation of tyrosine kinase networks during prostate cancer progression. Proc Natl Acad Sci USA. 109:1643–1648. 2012. View Article : Google Scholar : PubMed/NCBI
49	Carey AM, Pramanik R, Nicholson LJ, et al: Ras-MEK-ERK signaling cascade regulates androgen receptor element-inducible gene transcription and DNA synthesis in prostate cancer cells. Int J Cancer. 121:520–527. 2007. View Article : Google Scholar
50	Weber MJ and Gioeli D: Ras signaling in prostate cancer progression. J Cell Biochem. 91:13–25. 2004. View Article : Google Scholar : PubMed/NCBI
51	Gioeli D, Wunderlich W, Sebolt-Leopold J, et al: Compensatory pathways induced by MEK inhibition are effective drug targets for combination therapy against castration-resistant prostate cancer. Mol Cancer Ther. 10:1581–1590. 2011. View Article : Google Scholar : PubMed/NCBI
52	Steelman LS, Abrams SL, Shelton JG, et al: Dominant roles of the Raf/MEK/ERK pathway in cell cycle progression, prevention of apoptosis and sensitivity to chemotherapeutic drugs. Cell Cycle. 9:1629–1638. 2010. View Article : Google Scholar : PubMed/NCBI
53	Zelivianski S, Spellman M, Kellerman M, et al: ERK inhibitor PD98059 enhances docetaxel-induced apoptosis of androgen-independent human prostate cancer cells. Int J Cancer. 107:478–485. 2003. View Article : Google Scholar : PubMed/NCBI
54	Menzies AM and Long GV: Dabrafenib and Trametinib, alone and in combination for BRAF-mutant metastatic melanoma. Clin Cancer Res. 20:2035–2043. 2014. View Article : Google Scholar : PubMed/NCBI
55	Schadendorf D, Amonkar MM, Milhem M, et al: Functional and symptom impact of trametinib versus chemotherapy in BRAF V600E advanced or metastatic melanoma: quality-of-life analyses of the METRIC study. Ann Oncol. 25:700–706
56	Anforth R, Liu M, Nguyen B, et al: Acneiform eruptions: A common cutaneous toxicity of the MEK inhibitor trametinib. Australas J Dermatol. View Article : Google Scholar : 2013.[Epub ahead of print].
57	Kim KB, Kefford R, Pavlick AC, et al: Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor. J Clin Oncol. 31:482–489. 2013. View Article : Google Scholar : PubMed/NCBI
58	Giacinti C and Giordano A: RB and cell cycle progression. Oncogene. 25:5220–5227. 2006. View Article : Google Scholar : PubMed/NCBI
59	Sellers WR and Kaelin WG Jr: Role of the retinoblastoma protein in the pathogenesis of human cancer. J Clin Oncol. 15:3301–3312. 1997.PubMed/NCBI
60	Grasso CS, Wu YM, Robinson DR, et al: The mutational landscape of lethal castration-resistant prostate cancer. Nature. 487:239–243. 2012. View Article : Google Scholar : PubMed/NCBI
61	Sharma A, Yeow WS, Ertel A, et al: The retinoblastoma tumor suppressor controls androgen signaling and human prostate cancer progression. J Clin Invest. 120:4478–4492. 2010. View Article : Google Scholar : PubMed/NCBI
62	Dyson N: The regulation of E2F by pRB-family proteins. Genes Dev. 12:2245–2262. 1998. View Article : Google Scholar : PubMed/NCBI
63	Mashal RD, Lester S, Corless C, et al: Expression of cell cycle-regulated proteins in prostate cancer. Cancer Res. 56:4159–4163. 1996.PubMed/NCBI
64	Drobnjak M, Osman I, Scher HI, Fazzari M and Cordon-Cardo C: Overexpression of cyclin D1 is associated with metastatic prostate cancer to bone. Clin Cancer Res. 6:1891–1895. 2000.PubMed/NCBI
65	Aparicio A, Den RB and Knudsen KE: Time to stratify? The retinoblastoma protein in castrate-resistant prostate cancer. Nat Rev Urol. 8:562–568. 2011. View Article : Google Scholar : PubMed/NCBI
66	Tan HL, Sood A, Rahimi HA, et al: Rb loss is characteristic of prostatic small cell neuroendocrine carcinoma. Clin Cancer Res. 20:890–903. 2014. View Article : Google Scholar : PubMed/NCBI
67	Nathwani SM, Cloonan SM, Stronach M, et al: Novel microtubule-targeting agents, pyrrolo-1,5-benzoxazepines, induce cell cycle arrest and apoptosis in prostate cancer cells. Oncol Rep. 24:1499–1507. 2010. View Article : Google Scholar : PubMed/NCBI
68	Reiner T, de las Pozas A and Perez-Stable C: Sequential combinations of flavopiridol and docetaxel inhibit prostate tumors, induce apoptosis, and decrease angiogenesis in the Ggamma/T-15 transgenic mouse model of prostate cancer. Prostate. 66:1487–1497. 2006. View Article : Google Scholar
69	Gomez LA, de Las Pozas A and Perez-Stable C: Sequential combination of flavopiridol and docetaxel reduces the levels of X-linked inhibitor of apoptosis and AKT proteins and stimulates apoptosis in human LNCaP prostate cancer cells. Mol Cancer Ther. 5:1216–1226. 2006. View Article : Google Scholar : PubMed/NCBI
70	Willder JM, Heng SJ, McCall P, Adams CE, Tannahill C, Fyffe G, Seywright M, Horgan PG, Leung HY, Underwood MA and Edwards J: Androgen receptor phosphorylation at serine 515 by Cdk1 predicts biochemical relapse in prostate cancer patients. Br J Cancer. 15:139–148. 2013.PubMed/NCBI
71	Gilbert MR, Dignam J, Pugh S, et al: Reply to m. C Chamberlain J Clin Oncol. 32:1634–1635. 2014. View Article : Google Scholar : PubMed/NCBI
72	Vici P, Capomolla E, Foggi P, et al: High activity of salvage treatment with biweekly paclitaxel-gemcitabine combination in heavily pretreated breast cancer patients. J Exp Clin Cancer Res. 25:39–44. 2006.PubMed/NCBI
73	Wang X, Hawk N, Yue P, et al: Overcoming mTOR inhibition-induced paradoxical activation of survival signaling pathways enhances mTOR inhibitors’ anticancer efficacy. Cancer Biol Ther. 7:1952–1958. 2008.PubMed/NCBI
74	Chu S, Holtz M, Gupta M and Bhatia R: BCR/ABL kinase inhibition by imatinib mesylate enhances MAP kinase activity in chronic myelogenous leukemia CD34⁺ cells. Blood. 103:3167–3174. 2004. View Article : Google Scholar : PubMed/NCBI
75	Yu C, Krystal G, Varticovksi L, et al: Pharmacologic mitogen-activated protein/extracellular signal-regulated kinase kinase/ mitogen-activated protein kinase inhibitors interact synergistically with STI571 to induce apoptosis in Bcr/Abl-expressing human leukemia cells. Cancer Res. 62:188–199. 2002.
76	Packer LM, Rana S, Hayward R, et al: Nilotinib and MEK inhibitors induce synthetic lethality through paradoxical activation of RAF in drug-resistant chronic myeloid leukemia. Cancer Cell. 20:715–727. 2011. View Article : Google Scholar : PubMed/NCBI
77	Dickson MA and Schwartz GK: Development of cell-cycle inhibitors for cancer therapy. Curr Oncol. 16:36–43. 2009.PubMed/NCBI